These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38287659)

  • 1. Risk Factors and Clinical Outcomes of COVID-19 Infection in Multiple Sclerosis Patients: A Retrospective Study from a Single Center in Kosovo.
    Komoni E; Jashari F; Boshnjaku D; Myftiu B; Pushka M; Blyta A; Nallbani-Komoni R
    Med Sci Monit; 2024 Jan; 30():e942992. PubMed ID: 38287659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
    Stoll S; Desai S; Levit E
    Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study.
    Zeineddine M; Al-Hajje A; Salameh P; Massouh J; Saab G; Al-Roughani R; Ahmed SF; Al-Mahdawi A; Shalaby N; Inshasi J; Sahraian MA; Gouider R; Mrabet S; Al-Khabouri J; Shayganneja V; Chentouf A; Boumediene F; Yamout B
    Mult Scler Relat Disord; 2024 Oct; 90():105790. PubMed ID: 39121598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
    Louapre C; Collongues N; Stankoff B; Giannesini C; Papeix C; Bensa C; Deschamps R; Créange A; Wahab A; Pelletier J; Heinzlef O; Labauge P; Guilloton L; Ahle G; Goudot M; Bigaut K; Laplaud DA; Vukusic S; Lubetzki C; De Sèze J; ; Derouiche F; Tourbah A; Mathey G; Théaudin M; Sellal F; Dugay MH; Zéphir H; Vermersch P; Durand-Dubief F; Françoise R; Androdias-Condemine G; Pique J; Codjia P; Tilikete C; Marcaud V; Lebrun-Frenay C; Cohen M; Ungureanu A; Maillart E; Beigneux Y; Roux T; Corvol JC; Bordet A; Mathieu Y; Le Breton F; Boulos DD; Gout O; Guéguen A; Moulignier A; Boudot M; Chardain A; Coulette S; Manchon E; Ayache SS; Moreau T; Garcia PY; Kumaran D; Castelnovo G; Thouvenot E; Taithe F; Poupart J; Kwiatkowski A; Defer G; Derache N; Branger P; Biotti D; Ciron J; Clerc C; Vaillant M; Magy L; Montcuquet A; Kerschen P; Coustans M; Guennoc AM; Brochet B; Ouallet JC; Ruet A; Dulau C; Wiertlewski S; Berger E; Buch D; Bourre B; Pallix-Guiot M; Maurousset A; Audoin B; Rico A; Maarouf A; Edan G; Papassin J; Videt D
    JAMA Neurol; 2020 Sep; 77(9):1079-1088. PubMed ID: 32589189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
    Smith JB; Gonzales EG; Li BH; Langer-Gould A
    JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?
    Immovilli P; Schiavetti I; Franceschini A; De Mitri P; Gelati L; Rota E; Guidetti D
    Mult Scler Relat Disord; 2024 May; 85():105547. PubMed ID: 38518506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
    Zabalza A; Arrambide G; Tagliani P; Cárdenas-Robledo S; Otero-Romero S; Esperalba J; Fernandez-Naval C; Trocoli Campuzano J; Martínez Gallo M; Castillo M; Bonastre M; Resina Sallés M; Beltran J; Carbonell-Mirabent P; Rodríguez-Barranco M; López-Maza S; Melgarejo Otálora PJ; Ruiz-Ortiz M; Pappolla A; Rodríguez Acevedo B; Midaglia L; Vidal-Jordana A; Cobo-Calvo A; Tur C; Galán I; Castilló J; Río J; Espejo C; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study.
    Jin H; Geiger C; Jessop N; Pedotti R; Raposo C; Whitley L; Brown JS; Muros-Le Rouzic E
    Mult Scler Relat Disord; 2023 Nov; 79():104943. PubMed ID: 37716211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
    Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
    Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
    Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
    EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia.
    Alshamrani F; Alnajashi H; AlJumah M; Almuaigel M; Almalik Y; Makkawi S; Alsalman S; Almejally M; Qureshi S; Aljarallah S; AlKhawajah N; Kedah H; Alotaibi H; Saeedi J; Alamri A
    Mult Scler Relat Disord; 2021 Jul; 52():103004. PubMed ID: 34049217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
    Simpson-Yap S; Pirmani A; Kalincik T; De Brouwer E; Geys L; Parciak T; Helme A; Rijke N; Hillert JA; Moreau Y; Edan G; Sharmin S; Spelman T; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton RM; Salter A; Bebo B; Van der Walt A; Butzkueven H; Ozakbas S; Boz C; Karabudak R; Alroughani R; Rojas JI; van der Mei IA; Sciascia do Olival G; Magyari M; Alonso RN; Nicholas RS; Chertcoff AS; de Torres AZ; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Peeters LM
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36038263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of SARS-CoV-2 Infection in Unvaccinated Multiple Sclerosis Patients on Disease-Modifying Therapies.
    Al-Shammri S; Chadha G; Chattopadhyay A; Doi S
    Med Princ Pract; 2023; 32(2):143-148. PubMed ID: 37231972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.